This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX)

Tipranks - Tipranks - Sat May 9, 3:56AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX).

Claim 55% Off TipRanks

Alcon (ALC)

UBS analyst Graham Doyle maintained a Buy rating on Alcon today and set a price target of CHF86.00. The company’s shares closed last Thursday at $63.88.

According to TipRanks.com, Doyle is ranked #10724 out of 12242 analysts.

Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $92.95, a 42.7% upside from current levels. In a report issued on April 24, TipRanks – PerPlexity also upgraded the stock to Buy with a CHF71.00 price target.

See the top stocks recommended by analysts >>

Argenx Se (ARGX)

In a report released today, Xian Deng from UBS maintained a Hold rating on Argenx Se, with a price target of $850.00. The company’s shares closed last Thursday at $787.31.

Deng has an average return of 16.4% when recommending Argenx Se. ;'>

According to TipRanks.com, Deng is ranked #1216 out of 12242 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1038.44 average price target.

Definium Therapeutics (DFTX)

In a report released today, Ami Fadia from Needham maintained a Buy rating on Definium Therapeutics, with a price target of $38.00. The company’s shares closed last Thursday at $23.20.

According to TipRanks.com, Fadia is a 5-star analyst with an average return of 31.3% and a 57.0% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, MapLight Therapeutics, Inc., and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Definium Therapeutics with a $40.08 average price target, a 70.4% upside from current levels. In a report issued on April 23, TipRanks – Google also upgraded the stock to Buy with a $26.00 price target.

Read More on ALC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).